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The prevalence of patent interferences in gene technology
Abstract
Unlike all other countries in the world, the United States awards patents to the first to invent, not to the first to
file an application for a patent. In cases where two or more inventors submit patent applications claiming the
same invention, an interference may be declared. Interference is the process by which the US Patent &
Trademark Office (USPTO; Washington, DC, USA) determines which of the applicants was the first to invent
and diligently reduce the invention to practice. More than half of these are resolved in favor of the inventor
who was the first-to-file, raising questions about whether this unique system is worth retaining. Interferences
are relatively rare. For the period 1998-2002, an average of four interferences were declared for every 10,000
patent applications filed. Data we have gathered suggest that interference proceedings in gene discovery and
biotechnology are much more prevalent than other areas of technology. The resulting legal fees are costing the
biotechnology industry millions of dollars each year.
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Competition in research 
 Unlike all other countries in the world, the US awards patents to the first to invent, not to 
the first to file an application for a patent.  In cases where 2 or more inventors submit patent 
applications claiming the same invention, an interference may be declared.  Interference is the 
process by which the US Patent & Trademark Office (USPTO) determines which of the 
applicants was the first to invent and diligently reduce the invention to practice.   
 Interferences are relatively rare.  For the period 1998-2002, there were an average of 4 
interferences declared for every 10,000 patent applications filed.  More than half of these are 
resolved in favor of the inventor who was the first to file, raising questions about whether this 
unique system is worth retaining.1  Despite their rarity, interferences may provide useful insights 
about scientific and technological competition. 
 We are performing interview-based case studies on the discovery, patenting, and 
commercialization of genetic inventions for a set of 7 diseases having genetic causes (Canavan 
disease (CD), Chronic Myelogenous Leukemia (CML), Colon Cancers (CC), Cystic Fibrosis 
(CF), Factor V Leiden (FVL), Hereditary Hemochromatosis (HH), and Spinal Muscular Atrophy 
(SMA)).  Our cases were chosen to capture a range of genetic diseases, encompassing rare (CD), 
common (HH and CF), single gene (CD, CF, HH, FVL), multigenic (SMA, CC), and somatic 
(CML) diseases.  Except for CML, all of these diseases have at least one patent on a gene in 
which mutations are known to be associated with disease.  One has several patents on one gene 
(CF), and two have patents on multiple genes (CC, SMA).  Given the rarity of interferences, we 
were surprised to find in this small sample that patents on the genes in 2 of these cases (CF and 
FVL) had been involved in interferences.   
 To examine whether we were seeing evidence of a pattern, we secured from the USPTO 
data on the number of interferences declared and the number of patent applications filed each 
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year for FY 1998 through 2002.  The data is broken down by Technology Centers (TC), which 
are competency groupings within the USPTO.  The number of interferences declared in each 
technology field and the rate of interference declarations per 1,000 patent applications filed are 
summarized in the table. 
 These data show that, in any one year, the rate of interference declaration involving TC 
1600 (biotechnology and organic chemistry) was at least 2.5 times the rate of declaration in any 
other technology area, and was about 6.5 times the average rate of all other technologies for the 5 
year period (F*=63.6 with 1,7 dƒ, p<0.0001).  TC 1600 encompasses drugs, herbicides, 
pesticides, cosmetics, bioinformatics and other organic compounds, so this rate is not purely 
attributable to biotechnologies, much less human genetics.  Detailed data that would permit 
greater discrimination of technology involved or historical comparisons is unavailable.  
Nonetheless, staff in TC 1600 estimated that about 75% of interferences declared in the center 
involve biotechnologies (George Elliott, personal communication). 
 These data are consistent with our observations of very high levels of competition and, in 
some cases, outright races for genetic discoveries.2  Notable examples of competition in 
molecular biology include the discovery of the Y chromosome in males first made by Stevens in 
1905;3 the characterization of the structure of DNA;4 the hunt for HIV;5 and most recently the 
quest for the sequence of the SARS virus.6  Less well-known are the close competitions for 
discovery of genes for CF and familial breast and ovarian cancers, both of which involved 
numerous groups.  In the latter case, in the mid-1990s, multiple patents on closely related 
discoveries issued to Oncormed and Myriad Genetics on BRCA1.7  Myriad and their 
collaborators at the Universities of Utah and Pennsylvania similarly raced against a British and 
Duke University group on BRCA2, with US patents issuing to both and potentially overlapping 
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patents pending in Europe.  More recently, the 2001 discovery of the gene associated with the 
rare Familial Dysautonomia by 2 different research groups also may well result in an 
interference, since each group filed a patent application on the gene.8,9   
 The high level of competition in these cases suggests several things about the nature of 
the research.  First, without taking any credit away from the scientists so engaged, gene 
discovery has become ordinary.  Necessary intellectual knowhow is shared by many, and success 
is predicated upon the ability and luck in identifying, soliciting, and studying the “right” families 
and groups.  Second, as in other scientific fields, these discoveries build upon knowledge 
contributed by others, reflecting the codependent but competitive environment of science.10  
Molecular biology is data intensive, requiring the development of technologies (e.g., faster 
sequencers and gene chips) and sharing of large databases.  The field is relatively young, and the 
rate of discovery may still be increasing.  Given the large body of expertise in molecular biology 
and the large volume of information now available, there may be a flood of downstream 
discoveries and developments resulting from the sequencing of the human genome and a 
concomitant increase in competition and the volume of interferences in the near future. 
 Interferences are expensive, costing an estimated $100,000 to $500,000 to resolve.1  The 
biotechnology industry is strongly dependent upon patents, and the high costs of resolving 
interferences are clearly seen as justified.  In the 2 cases we studied, there were 3 nonprofit 
research institutions and 1 firm involved, and 2 of the nonprofit institutions licensed the patent 
applications to firms that bore the costs of the interferences.  This is consistent with an earlier 
survey of licensing and technology transfer executives in which we found that nonprofit research 
institutions often seek at a minimum to cover the costs of patent prosecution in their licensing of 
gene sequence patents.11 
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 There are several limitations to this study.  First, our raw data provide no information 
about the type of invention involved, and we have no ability to discriminate between cases 
involving genetic discoveries (i.e., sequences and their use) compared to other biotechnology 
inventions (e.g., devices).  Second, our finding of a high rate of interference declaration 
involving biotechnologies could be an artifact of the accuracy of computer searches by the PTO 
in discovering overlapping claims for genes, but how much this might contribute to the observed 
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TC TC subject matter FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 totals 
1600 
Biotechnology and organic 
chemistry 56 (2.1) 46 (1.5) 60 (1.8) 52 (1.4) 62 (1.5) 276 (1.6)
1700 
Chemical and materials 
engineering 34 (0.82) 21 (0.49) 24 (0.53) 31 (0.63) 22 (0.44) 132 (0.58)
2100 
Computer architecture, 
software & information  
security 3 (0.076) 1 (0.034) 4 (0.058)
2600 Communications 6 (0.14) 1 (0.024) 7 (0.082)
2700 
Communications and 
information processing 7 (0.14) 3 (0.052) 12 (0.16)  22 (0.12)
2800 
Semiconductors, electrical 
& optical systems and 
components 23 (0.45) 6 (0.11) 6 (0.098) 12 (0.17) 10 (0.14) 57 (0.18)
2900 
Designs for articles of 








products 34 (0.81) 10 (0.23) 9 (0.19) 10 (0.20) 7 (0.13) 70 (0.30)
totals  163 (0.64) 91 (0.33) 136 (0.44) 124 (0.36) 109 (0.31) 623 (0.40)
 
Legend: Annual number of patent interferences declared in each Technology Center 
field, and rate of interference declarations per 1,000 filed applications.  Source: USPTO.  
Note: TC 2700 was divided into Centers 2100 and 2600 at the beginning of FY2001.
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